Review anchor
Sodium-dependent dopamine transporter
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Sodium-dependent dopamine transporter
CHEMBL238
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Sodium-dependent dopamine transporter as ChEMBL target CHEMBL238, mapped to UniProt Q01959. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL238
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q01959
Sodium-dependent dopamine transporter
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Sodium-dependent dopamine transporter matters
Sodium-dependent dopamine transporter is reviewed as Sodium-dependent dopamine transporter (UniProt Q01959); Sodium-dependent dopamine transporter shows approved-linked disease relevance led by attention deficit hyperactivity disorder. 5 more disease programs remain visible in the same review block.; 13 linked drugs keep this evidence frame grounded.; the current evidence base includes 184 approved drugs, 7632 compounds, and 944 assays, with lead potency reaching pChEMBL 9.9.
Protein context
Sodium-dependent dopamine transporter
Sodium-dependent dopamine transporter Sequence length is 620 aa.
Review this target as Sodium-dependent dopamine transporter, mapped to UniProt Q01959. Sequence length is 620 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt Q01959
Protein
Disease context
attention deficit hyperactivity disorder
Sodium-dependent dopamine transporter shows approved-linked disease relevance led by attention deficit hyperactivity disorder. 5 more disease programs remain visible in the same review block. 13 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include AMPHETAMINE, AMPHETAMINE ASPARTATE, AMPHETAMINE SULFATE.
Start review with attention deficit hyperactivity disorder because it currently carries approved-linked support. Linked drugs include AMPHETAMINE, AMPHETAMINE ASPARTATE, AMPHETAMINE SULFATE, ARMODAFINIL. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Approved-linked
13 linked drugs
Activity base
Portfolio and assay base
ChEMBL currently tracks 184 approved drugs, 7632 compounds, and 944 assays for this target. The dominant activity type is IC50. CHEMBL353333 is the current potency anchor at pChEMBL 9.9.
Use CHEMBL353333 as the tractability anchor when discussing potency (pChEMBL 9.9).
Activity source · ChEMBL 36 via Core Engine
184 approved
pChEMBL 9.9
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Sodium-dependent dopamine transporter matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q01959, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why attention deficit hyperactivity disorder is currently treated as approved-linked support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
7632
Total Compounds
944
Total Assays
184
Approved Drugs
IC50: 3892.0, KI: 3409.0, EC50: 104.0, KD: 21.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL353333
|
9.9 | Ki | — |
|
|
No preferred name
CHEMBL1818444
|
9.8 | Ki | — |
|
|
No preferred name
CHEMBL42553
|
9.7 | Ki | — |
|
|
No preferred name
CHEMBL1818445
|
9.7 | Ki | — |
|
|
No preferred name
CHEMBL28394
|
9.7 | Ki | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
VILOXAZINE
CHEMBL306700
|
2021 |
|
|
COCAINE HYDROCHLORIDE
CHEMBL529437
|
2017 |
|
|
COCAINE
CHEMBL370805
|
2017 |
|
|
BREXPIPRAZOLE
CHEMBL2105760
|
2015 |
|
|
VILAZODONE HYDROCHLORIDE
CHEMBL1615374
|
2011 |
|
|
VILAZODONE
CHEMBL439849
|
2011 |
|
|
TICAGRELOR
CHEMBL398435
|
2010 |
|
|
INDACATEROL
CHEMBL1095777
|
2009 |
|
|
ARMODAFINIL
CHEMBL1201192
|
2007 |
|
|
DULOXETINE
CHEMBL1175
|
2004 |
|
|
DEXMETHYLPHENIDATE
CHEMBL827
|
2001 |
|
|
IOFLUPANE
CHEMBL1945778
|
2000 |
|
|
MODAFINIL
CHEMBL1373
|
1998 |
|
|
SIBUTRAMINE
CHEMBL1419
|
1997 |
|
|
REBOXETINE
CHEMBL14370
|
1997 |
|
|
CARVEDILOL
CHEMBL723
|
1995 |
|
|
NEFAZODONE
CHEMBL623
|
1994 |
|
|
FLUVOXAMINE
CHEMBL814
|
1994 |
|
|
NEFAZODONE HYDROCHLORIDE
CHEMBL1200492
|
1994 |
|
|
SALMETEROL
CHEMBL1263
|
1994 |
|
|
PAROXETINE
CHEMBL490
|
1992 |
|
|
SERTRALINE
CHEMBL809
|
1991 |
|
|
DOXAZOSIN
CHEMBL707
|
1990 |
|
|
EBASTINE
CHEMBL305660
|
1990 |
|
|
ASTEMIZOLE
CHEMBL296419
|
1988 |
|
|
BUPROPION
CHEMBL894
|
1985 |
|
|
TERFENADINE
CHEMBL17157
|
1985 |
|
|
NOMIFENSINE
CHEMBL273575
|
1984 |
|
|
CYCLIZINE
CHEMBL648
|
1982 |
|
|
ECONAZOLE
CHEMBL808
|
1982 |
|
|
ETHINYL ESTRADIOL
CHEMBL691
|
1982 |
|
|
DEXCHLORPHENIRAMINE
CHEMBL1201353
|
1981 |
|
|
DOBUTAMINE
CHEMBL926
|
1978 |
|
|
CLEMASTINE
CHEMBL1626
|
1977 |
|
|
PEMOLINE
CHEMBL1177
|
1975 |
|
|
OXYBUTYNIN
CHEMBL1231
|
1975 |
|
|
DOPAMINE
CHEMBL59
|
1974 |
|
|
MAZINDOL
CHEMBL781
|
1973 |
|
|
PYRILAMINE
CHEMBL511
|
1973 |
|
|
DIETHYLSTILBESTROL
CHEMBL411
|
1973 |
|
|
MITOTANE
CHEMBL1670
|
1970 |
|
|
DESIPRAMINE
CHEMBL72
|
1964 |
|
|
METHYLPHENIDATE
CHEMBL796
|
1955 |
|
|
METHYLPHENIDATE HYDROCHLORIDE
CHEMBL1722
|
1955 |
|
|
DEXTROAMPHETAMINE
CHEMBL612
|
1955 |
|
|
BENZTROPINE
CHEMBL1201203
|
1954 |
|
|
PYROVALERONE
CHEMBL201960
|
— |
Source Header